This week, Samsung, the parent company of Samsung BioLogics and biosimilar development company Samsung Bioepis, announced plans to invest $22 billion across business lines, including biopharmaceuticals.
This week, Samsung, the parent company of Samsung BioLogics and biosimilar development company Samsung Bioepis, announced plans to invest $22 billion across business lines including biopharmaceuticals.
“For biopharmaceuticals, Samsung has seen strong growth from both its contract manufacturing and biosimilar businesses. It will continue to invest heavily in the businesses, including developing and manufacturing biosimilars to combat chronic and difficult-to-cure diseases,” read the statement.
Samsung has already taken an active role to further invest in its biosimilar business with the creation of a new manufacturing plant in Songdo, Incheon, Republic of Korea, its third in this location. With the completion of this plant, the company will have the total production capacity of 362,000 liters and will have invested $2.6 billion (3 trillion won), in manufacturing capabilities. Commercial production is expected to begin at this plant in 2020.
Click here to read more about Samsung Bioepis.
Though the production capabilities of the company have increased, last month, Samsung BioLogics reported earnings that included a net loss of $8.53 million (9.6 billion won) in the second quarter. It also reported that the operating profit of the company increased by $1.2 million (13.7 billion won) from the quarter prior and showed improvement in its net loss, as sales had improved from its Samsung Bioepis subsidiary, a joint venture with Biogen.
Accounting practices at Samsung BioLogics were recently called into question, however, when South Korea’s financial regulator, the Securities and Futures Commission (SFC), found that Samsung BioLogics had not disclosed that Biogen had the option to increase its stake in the joint venture with Samsung Bioepis to 49.9%.
“The SFC concluded that Samsung BioLogics had violated accounting standards by intentionally omitting information regarding it joint venture agreement with Biogen in its public disclosure,” read the announcement from the SFC.
The agency has mandated sanctions against Samsung BioLogics including a request for dismissal of executives in charge, designation of external auditors for the next 3 years, and referral to prosecutors. Additionally, the company’s current auditor would be barred from auditing the company for 4 years and would also be referred to prosecutors for violation of auditing standards.
Just last month, the FDA granted Samsung BioLogics approval for its first completed monoclonal antibody at the first of its 3 plants. The product nor the client it was manufactured for were disclosed.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.